Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View

Author(s): Roberta Filograna, Mariano Beltramini, Luigi Bubacco and Marco Bisaglia

Volume 14 , Issue 3 , 2016

Page: [260 - 271] Pages: 12

DOI: 10.2174/1570159X13666151030102718

Price: $65

Abstract

Parkinson’s disease (PD) is a degenerative neurological syndrome, which is characterized by the preferential death of dopaminergic (DAergic) neurons in the Substantia Nigra. The pathogenesis of this disorder remains poorly understood and PD is still incurable. Current drug treatments are aimed primarily for the treatment of symptoms to improve the quality of life. Therefore, there is a need to find out new therapeutic strategies that not only provide symptomatic relief but also halt or reverse the neuronal damage hampering PD progression. Oxidative stress has been identified as one of the major contributors for the nigral loss in both sporadic and genetic forms of PD. In this review we first evaluate the current literature that links oxidative stress and mitochondrial dysfunction to PD. We then consider the results obtained through the treatment of animal models or PD patients with molecules that prevent oxidative stress or reduce mitochondrial dysfunction.

Keywords: Antioxidants, iron chelators, mitochondria, oxidative stress, radical scavengers, reactive oxygen species.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy